Compare ERII & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | FLGT |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 867.4M |
| IPO Year | 2008 | 2016 |
| Metric | ERII | FLGT |
|---|---|---|
| Price | $13.90 | $27.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $16.50 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 450.6K | 220.2K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.56 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $135,191,000.00 | ★ $315,549,000.00 |
| Revenue This Year | $5.93 | $16.84 |
| Revenue Next Year | $8.97 | $9.74 |
| P/E Ratio | $38.72 | ★ N/A |
| Revenue Growth | 0.10 | ★ 13.61 |
| 52 Week Low | $10.86 | $14.57 |
| 52 Week High | $18.32 | $31.04 |
| Indicator | ERII | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 44.79 |
| Support Level | $13.68 | $26.63 |
| Resistance Level | $14.75 | $28.26 |
| Average True Range (ATR) | 0.34 | 0.66 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 13.41 | 14.65 |
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.